author photo

November 30, 2009

Jeremy GrushcowJeremy is a corporate lawyer at Ogilvy Renault LLP focused on life science, cleantech and other technology-intensive transactions. He has two kids, a Ph.D. in Molecular Genetics and Cell Biology, and his very own blog.
[click on the author's name for more information]

This Week’s Biotech Highlights

With our friends south of the border still reeling from a turkey-induced hangover, it was a quiet week. Still, there was plenty to be thankful for.

Proponents of personalized medicine were thankful for several developments that show this trend is picking up speed: CVS followed Medco’s example in expanding pharmacogenomic testing, while biotech and pharma companies, as well as the National Cancer Institute, stepped up their investment in the field.

I am thankful to be following a new trend for 2010: synthetic biology, i.e. attempts to create novel organisms. This week, I weighed in on the search for the smallest genome that could constitute a living organism, noting that the most popular candidate seems to be proving itself to be a red herring.

Finally, I am thankful for Richard Chan, our science writer, who has taken over responsibility for the Friday Science Review, and for Jacob Cawker, who provides research support for the Monday Biotech Deal Review. Thanks guys – I couldn’t do it without you!

up

Make a comment:

Note that some comments may be moderated. If you have not had an approved comment here before, your comment will be held for approval. We are glad to publish comments that address issues raised in the post or other comments on it and that contribute to a fruitful discussion. We do not publish comments that seek to promote commercial products or that seek personal legal advice.

Although we do not require it, we ask that in making a comment you use your full name. You must supply a valid email address, which will not appear with your comment.

Switch to our mobile site